Stanford University — Preclinical Research on Hepatitis B (Jeffrey Glenn)

[Human Health and Wellbeing] Grant investigators: Chris Somerville and Heather Youngs This page was reviewed but not written by the grant investigators. Stanford University staff also reviewed this page prior to publication. Open Philanthropy recommended a grant of $915,000 to Stanford University to support preclinical research on the development of a drug to cure chronic hepatitis B virus (HBV) infections and prevent HBV-induced liver cancer, led by Professor Jeffrey Glenn. If effective, the new drug could replace existing drugs that treat, but do not cure, the disease. Approximately 250 million people globally have chronic HBV, many of whom develop fatal liver cancer. This falls within our work on scientific research, specifically within our interest in advancing human health and wellbeing.